Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
- Author:
Ashraf Mahmoud EL-ENBABY
1
;
Nadia Ahmed Abd EL MONEIM
;
Gehan Abd EL ATTI KHEDR
;
Yasmine Mohamed Nagy ELWANY
Author Information
- Publication Type:Original Article
- Keywords: Trastuzumab; HER2; Adjuvant chemotherapy; Radiotherapy; Echocardiography
- MeSH: Breast Neoplasms; Breast; Chemotherapy, Adjuvant; Disease-Free Survival; Echocardiography; Epidermal Growth Factor; Follow-Up Studies; Humans; Radiotherapy; Trastuzumab
- From: Korean Journal of Clinical Oncology 2018;14(2):108-115
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival. Secondary endpoints included cardiac safety, tolerability, and overall survival.METHODS: The study included 60 non-metastatic HER2-positive breast cancer patients. All study patients underwent surgery, received adjuvant chemotherapy, radiotherapy and hormonal therapy if indicated. Thirty patients were randomized in each group. Group I patients received adjuvant trastuzumab for 12 months, while group II patients received adjuvant trastuzumab for 9 months. Patients were assessed by clinical examination and Echocardiography during treatment.RESULTS: After median follow-up of 12 months, 90% of the patients in group I were disease free and 83.3% of patients in group II were disease free (P=0.402). All studied population in both groups I and II were alive at the end of the 1-year follow-up period after the completion of adjuvant trastuzumab treatment thus overall survival is 100%.CONCLUSION: Trastuzumab is tolerable and its side effects are reversible. Nine months of adjuvant trastuzumab treatment is more cost effective than the standard 12 months.
